News Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Real-time Estimate Cboe BZX Other stock markets 09:00:00 02/05/2024 pm IST			5-day change	1st Jan Change
12.88 ^USD	+1.74%		+8.00%	-29.16%

12/03	Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	CI
05/03	RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Pliant Therapeutics to Participate in Upcoming Investor Events	01/05	GL
Pliant Therapeutics to Participate in Upcoming Investor Events	01/05	AQ
Pliant Therapeutics to Participate in Upcoming Investor Events	02/04	GL
Pliant Therapeutics Announces Upcoming Presentations at the 2024 American Thoracic Society International Conference	27/03	GL
Nimbus Therapeutics Appoints Katharine Knobil, M.D., to Board of Directors	13/03	AQ
Pliant Therapeutics, Inc. Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03	CI
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03	GL
Pliant Therapeutics Announces Accelerated Bexotegrast Development Plan for the Treatment of Idiopathic Pulmonary Fibrosis	12/03	AQ
RBC Lifts Price Target on Pliant Therapeutics to $54 From $50, Says Bexotegrast Could Have Multi-Billion-Dollar Revenue Opportunity; Outperform, Speculative Risk Kept	05/03	MT
Pliant Therapeutics : March 2024 Corporate Presentation	29/02	PU
RBC Cuts Price Target on Pliant Therapeutics to $50 From $53, Keeps Outperform, Speculative Risk	28/02	MT
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	28/02	GL
Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2023 Financial Results	28/02	AQ
Pliant Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	28/02	CI
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02	GL
Pliant Therapeutics to Participate in Upcoming Investor Conferences	26/02	AQ
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02	GL
Pliant Therapeutics to Participate in Upcoming Investor Events	07/02	AQ
Oppenheimer Adjusts Pliant Therapeutics Price Target to $47 From $49, Maintains Outperform Rating	06/02	MT
Transcript : Pliant Therapeutics, Inc. - Special Call	05/02

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Pliant Therapeutics, Inc.

Equities

PLRX

US7291391057

Summary

Filters